As Concern Grows over Effectiveness and Safety of Trial Vaccines CSO Ebola Task Force Holds Big Stakeholders Dialogue Today


As the Ebola vaccine trials that began early this month continue in several locations in and around Monrovia, the National Civil Society Organization Task Force on Ebola is expected to hold a major dialogue today at the Stella Maris Polytechnic campus.

The dialogue, according to the CSO Ebola Task Force will demand some explanations from its co-investigator, Dr. Stephen Kennedy and the Dean of the A.M. Dogliotti College of Medicine of the University of Liberia, Dr. Vuyu K. Golakai.

A statement quoting the CSO indicates that medical practitioners, representatives of diplomatic missions in Liberia, academicians, nursing students, journalists and other civil society organizations are expected to attend.

The dialogue, according to the statement, will seek clarity from Dr. Kennedy and his colleagues about progress and challenges in the trial of the CHAD-3 and VSV Vaccines that are expected to inoculate about 600 people in the country.

Furthermore, the statement notes, the dialogue will seek clarity from the Liberian doctors about the long and short-term public health implications of the vaccine on the country, noting with concern that Liberia is the first to undergo such a trial in West Africa.

The discourse is also intended to ascertain the ethics and role of the Liberia medical society in the ongoing trial.

Accordingly, the event will be recorded and played on seven Monrovia-based radio stations and several community radio stations across Liberia.

The dialogue is under the theme, “Ebola vaccine trial and its implications on Public Health in Liberia.” There are 35 civil society groups under the National Civil Society Task Force on Ebola initiating public dialogue to create awareness on the virus and to seek accountability of funds for the fight.

The group is supported by non-governmental organizations, including USAID, OSIWA, IBIS, IREX and Action Aid.


Please enter your comment!
Please enter your name here